Oncolytics Announces Up To $80M At-The-Market Facility
Oncolytics Announces Up To $80M At-The-Market Facility
SAN DIEGO, Calif. and CALGARY, AB, March 5, 2021 /CNW/ ---- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that it has entered into an at-the-market (ATM) equity offering sales agreement with Canaccord Genuity LLC. The ATM allows the Company, at its sole discretion, to issue common shares from treasury, at prevailing market prices, with an aggregate gross sales amount of up to US$80 million. The company has no obligation to sell any shares pursuant to the ATM. The ATM provides Oncolytics the option to efficiently tap into the financial markets as needed to support ongoing business development activities and clinical trials, while bolstering management's ability to negotiate potential business development agreements from a position of financial strength.
加利福尼亚州圣迭戈和阿肯色州卡尔加里，2021年3月5日/CNW/Oncolytics Biotech®Inc.(纳斯达克：Oncy)(多伦多证券交易所：ONC)，目前正在开发的Pelareorep是一种静脉注射的免疫溶瘤病毒，今天宣布它已经与Canaccel Genuity LLC签订了一项在市场上(ATM)股权发行的销售协议。自动取款机允许公司自行决定以当时的市场价格从库房发行普通股，总销售额最高可达8000万美元。根据自动取款机，该公司没有义务出售任何股份。自动取款机为Oncolytics公司提供了根据需要有效地进入金融市场的选择，以支持正在进行的业务开发活动和临床试验，同时加强管理层从财务实力的立场谈判潜在业务开发协议的能力。
In connection with the ATM, Oncolytics has filed a Prospectus Supplement with the Alberta Securities Commission and with the United States Securities and Exchange Commission, which supplements Oncolytics' Canadian short form base shelf prospectus dated June 12, 2020, and Oncolytics' shelf registration statement on Form F-10 declared effective on June 15, 2020 by the United States Securities and Exchange Commission. Sales of the ATM offering will only be conducted in the United States through NASDAQ or another exchange at market prices. No sales will be conducted in Canada or through the Toronto Stock Exchange.
关于自动取款机，Oncolytics公司已经向艾伯塔省证券委员会和美国证券交易委员会提交了一份说明书补充文件，补充了Oncolytics公司于2020年6月12日发布的加拿大短格式基础货架招股说明书和美国证券交易委员会宣布于2020年6月15日生效的Oncolytics公司F-10表格的货架登记声明。自动柜员机产品的销售将仅在美国通过纳斯达克或另一家交易所以市场价格进行。不会在加拿大或通过多伦多证券交易所进行销售。
A copy of the Prospectus Supplement is available on SEDAR at www.sedar.com and on EDGAR at www.sec.gov or may be obtained upon request to Oncolytics' Investor Relations Department using the contact information set out below. Before you invest, you should read the Prospectus Supplement and accompanying base shelf prospectus and the other documents the Company has filed with the SEC for more complete information about the Company and the ATM offering. Alternatively, a copy of the Prospectus Supplement and accompanying base shelf prospectus are available upon request by contacting Canaccord Genuity LLC Attention: Syndicate Department, 99 High Street, Suite 1200, Boston, MA 02110, Attn: Equity Syndicate Department, by telephone at (617) 371-3900 or by e-mail at prospectus@cgf.com.
招股说明书补编的副本可在SEDAR上查阅，网址为Www.sedar.com和埃德加在Www.sec.gov或者可以使用下面列出的联系信息向Oncolytics的投资者关系部提出要求。在您投资之前，您应该阅读招股说明书附录和随附的基本架子招股说明书，以及公司提交给证券交易委员会的其他文件，以获得有关公司和自动取款机产品的更完整信息。或者，如有要求，可联系Canaccel Genuity有限责任公司索取招股说明书副刊和基础架子招股说明书。联系地址：Syndicate Department，99 High Street，Suite1200，Boston，MA 02110，Attn：Equity Syndicate Department，电话：(617371-3900)，或发送电子邮件至邮箱：prospectus@cgf.com.
译文内容由第三方软件翻译。